ATLANTA, GA--(Marketwired - Jan 7, 2014) - MissionIR today announces the online availability of its interview with VolitionRx (OTCQB: VNRX) president and Chief Executive Officer Cameron Reynolds. The full audio interview is available at http://vnrx.missionir.com/interview.html.
VolitionRx is a cancer diagnostics company focused on bringing to market its inexpensive, accurate, and minimally invasive cancer detection blood tests. The company's initial focus is on diagnostic testing for colorectal cancer, the third most common cancer diagnosed in the United States.
The company recently commenced a large clinical trial involving 16,000 patients to assess the accuracy of Volition's blood-based test. While the current focus is on developing a diagnostic test for colorectal cancer, future plans call for expansion into detection of various other cancers as well. For the time being, however, the company recognizes the great need for developing less expensive, less invasive, but accurate screening tests.
"Being a small company and colorectal being a multi-billion dollar market in itself, we're focusing on getting product out for that. But it's certainly something we'd be very keen to expand into other cancers as soon as we're through the process of developing this diagnostic for colorectal cancer," Reynolds says.
In addition to detailing the significant accuracy of blood-based tests, Reynolds discusses his own extensive professional background as well as that of the company's management and scientific teams, which collectively have decades of relative experience.
Reynolds also recaps several of Volition's recent significant achievements and provides insight into what to expect out of the company in 2014.
"It's been a very pivotal year for the company and next year we'll begin to get the results from this large clinical trial coming through, so there are some very large data points coming in the first few quarters of the year, which if they continue to go well will be transformational for the company and really put us on the map as a very stable, technologically superior platform for detecting colorectal cancer," he says. "... We're beginning the process next year of beginning legal ability to sell our tests in Europe and start the process of U.S. FDA trials."
Wrapping up the interview, Reynolds notes that Volition aims to uplist to a major stock exchange in the second half of 2014 to fully access capital markets and continue company growth.
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream -- an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
For additional information, please visit the Company's corporate Website: www.VolitionRx.com
This press release may contain "forward-looking statements." Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.